TML-OHC-19

TML-OHC-19 is a preclinical-stage pharmaceutical candidate developed by Themis Medicare. It utilizes a Novel Drug Delivery System (NDDS) to provide a long-acting formulation of vitamins, specifically targeting the sustained release of hydroxocobalamin (Vitamin B12). The "OHC" in the code name refers to hydroxocobalamin, suggesting the drug is designed to maintain therapeutic plasma levels over an extended period, potentially reducing the frequency of administration for patients with vitamin deficiencies. This approach aims to improve patient compliance and therapeutic outcomes compared to conventional immediate-release vitamin supplements.

Other names

TML-OHC-19-Themis Medicare-NDDS-Long Acting VitaminsTML-OHC19-Themis Medicare-NDDS-Long Acting VitaminsTML-OHC 19-Themis Medicare-NDDS-Long Acting Vitamins